Patient Care

Posted: Mar 7, 2016 by ITOG Administrator

Update on the interNational Anaplastic Thyroid cancer Tissue bank project (iNATT) www.inatt.org

iNATT
The interNational Anaplastic Thyroid Cancer Tissue Bank and Database project (iNATT) was launched in the UK in 2013 and extended internationally in 2014.

Posted: Dec 18, 2015 by ITOG Administrator

Update on ITOG Selumetinib Trial

Dr. Alan Ho
The selumetinib clinical trial led by Dr. Alan Ho of Memorial Sloan Kettering Cancer Center in New York, NY is now open. The trial evaluates the effectiveness of selumetinib to enhance uptake of radioactive iodine (RAI) for treatment of advanced thyroid cancer. This is a large, multicenter,...

Posted: Dec 18, 2015 by ITOG Administrator

Initial Findings of ITOG's First Clinical Trial

Dr. Manisha H. Shah
Preliminary results of the first clinical trial initiated by ITOG have been evaluated, marking a major accomplishment for ITOG. The goal of this multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, is to examine whether patients who had progression of their...

Posted: Feb 12, 2015 by ITOG Administrator

FDA Approves Lenvima for Thyroid Cancer based on SELECT results

A large, multi-center phase 3 study (SELECT trial) has found that patients with progressive, iodine refractory differentiated thyroid cancer have markedly improved progression free survival (PFS) when treated with lenvatinib, an oral tyrosine kinase inhibitor. Multiple ITOG members participated in...

Posted: Feb 11, 2015 by ITOG Administrator

ITOG Trial #1 Completes Enrollment

The first clinical trial initiated by ITOG in the fall of 2013 has completed its planned enrollment, marking a major accomplishment for ITOG.  The goal of this multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, is to examine whether patients who had...

Posted: Apr 2, 2014 by Yariv Houvras

Update on ITOG’s First Clinical Trial

ITOG's first clinical trial has reached 50% of patient accrual. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University,examines whether patients who had progression of their thyroid cancer on a VEGFR inhibitor benefit from treatment with Cabozantinib.

Posted: Oct 16, 2013 by Yariv Houvras

16th International Thyroid Cancer Survivors’ Conference

October 9, 2013 The 16th annual International Thyroid Cancer Survivors’ www.ThyCa.org conference took place from September 27-29, 2013 in Philadelphia. A record breaking 550 attendees came to the meeting. Through this conference, ThyCa is able to bring together the latest research, advances in...

Posted: Jun 13, 2013 by Yariv Houvras

Sorafenib Improves Thyroid Cancer Outcomes

(ASCO, June 2, 2013) A large phase III clinical trial reported that sorafenib improves progression free survival for patients with radioactive iodine refractory, differentiated thyroid cancer.

Contact

International Thyroid Oncology Group
5166 Commercial Drive
Yorkville, New York 13495